高级检索
当前位置: 首页 > 详情页

Thorombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: a multicenter randomized clinical trial

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ 中华系列

单位: [1]Chinese Acad Med Sci, Cardiovasc Inst, Dept Cardiol, Beijing 100037, Peoples R China [2]Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China [3]Shenyang No Hosp, Dept Cardiol, Shenyang 110840, Liaoning, Peoples R China [4]Beijing Chaoyang Hosp, Dept Cardiol, Beijing 100020, Peoples R China [5]Peking Univ, Dept Cardiol, Hosp 3, Beijing 100083, Peoples R China [6]Dalian Med Univ, Affiliated Hosp 1, Dept Cardiol, Dalian 116011, Liaoning, Peoples R China [7]Beijing Friendship Hosp, Dept Cardiol, Beijing 100050, Peoples R China [8]Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Cardiol, Sch Med, Shanghai 200025, Peoples R China [9]Liaoning Prov Peoples Hosp, Dept Cardiol, Shenyang 110016, Liaoning, Peoples R China [10]Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China [11]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China [12]Shanghai Sixth Peoples Hosp, Dept Cardiol, Shanghai 200233, Peoples R China [13]China Med Univ, Affiliated Hosp 1, Dept Cardiol, Shenyang 110001, Peoples R China [14]Sichuan Univ, Western China Publ Hlth Inst, Chengdu 610041, Sichuan, Peoples R China
出处:
ISSN:

关键词: acute myocardial infarction thorombolytic therapy rescue percutaneous coronary intervention primary percutaneous coronary intervention

摘要:
Background Although thrombolytic therapy with rescue percutaneous coronary intervention (PCI) is a common treatment strategy for ST-segment elevation acute myocardial infarction (STEMI), scant data are available on its efficacy relative to primary PCI, and comparison was therefore the aim of this study. Methods This multicenter, open-label, randomized, parallel trial was conducted in 12 hospitals on patients (age 570 years) with STEMI who presented within 12 hours of symptom onset (mean interval >3 hours). Patients were randomized to three groups: primary PCI group (n=101); recombinant staphylokinase (r-Sak) group (n=104); and recombinant tissue-type plasminogen activator (rt-PA) group (n=106). For all patients allocated to the thrombolytic therapy arm, coronary angiography was performed at 90 minutes after drug therapy to confirm infarct-related artery (IRA) patency; rescue PCI was performed in cases with TIMI flow grade <= 2. Bare-metal stent implantation was planned for all patients. Results After randomization it required an average of 113.4 minutes to start thrombolytic therapy (door-to-needle time) and 141.2 minutes to perform first balloon inflation in the IRA (door to balloon time). Rates of IRA patency (TIMI flow grade 2 or 3) and TIMI flow grade 3 were significantly lower in the thrombolysis group at 90 minutes after drug therapy than in the primary PCI group at the end of the procedure (70.5% vs. 98.0%, P <0.0001, and 53.0% vs. 85.9%, P <0.0001, respectively). Rescue PCI with stenting was performed in 117 patients (55.7%) in the thrombolytic therapy arm. Rates of patency and TIMI flow grade 3 were still significantly lower in the rescue PCI than in the primary PCI group (88.9% vs. 97.9%, P=0.0222, and 68.4% vs. 85.0%, P=0.0190, respectively). At 30 days post-therapy, mortality rate was significantly higher in the thrombolysis combined with rescue PCI group than in primary PCI group (7.1% vs. 0, P=0.0034). Rates of death/MI and bleeding complications were significantly higher in the thrombolysis with rescue PCI group than in the primary PCI group (10.0% vs. 1.0%, P=0.0380, and 28.10% vs. 8.91%, P=0.0001, respectively). Conclusions Thrombolytic therapy with rescue PCI was associated with significantly lower rates of coronary patency and TIMI flow grade 3, but with significantly higher rates of mortality, death/MI and hemorrhagic complications at 30 days, as compared with primary PCI in this group of Chinese STEMI patients with late presentation and delayed treatments. Chin Med J 2010;123(11):1365-1372

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2009]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
JCR分区:
出版当年[2008]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2008版] 出版当年五年平均[2004-2008] 出版前一年[2007版] 出版后一年[2009版]

第一作者:
第一作者单位: [1]Chinese Acad Med Sci, Cardiovasc Inst, Dept Cardiol, Beijing 100037, Peoples R China [2]Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Cardiovasc Inst, Dept Cardiol, Beijing 100037, Peoples R China [2]Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)